CCTG has launched a patient-centred observational study: SC27 Living With Cancer in the Time of COVID-19: A Cohort Study of the Impact of the COVID-19 Pandemic on Cancer Patients During Treatment and Survivors. The aim of this study is to examine the emotional and physical consequences of living with cancer during this pandemic and the impact it may have on your quality of life and changes in your cancer care and follow-up.
Venetoclax and Obinutuzumab vs DeLayed Therapy with VEnetoclax and Obinutuzumab in Asymptomatic High-Risk Patients with CLL/SLL (EVOLVE)
Economic Analysis of Early vs Delayed Therapy in Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pembrolizumab and Brentuximab Vedotin vs GDP Followed by High Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma
COMPASSHER2 Residual Disease, A Double-Blinded, Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Giving olaparib to patients with certain BRCA-mutated breast cancer for 1 year after they were treated with chemotherapy, surgery, or radiation significantly improved disease-free survival, according to the results that were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and were simultaneously published in the New England Journal of Medicine.
MRD Driven Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH clinical trials
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MAIN-CAV: Maintenance Cabozantinib and Avelumab vs Maintenance Avelumab After First-Line Platinum Based Chemotherapy in Metastatic Urothelial Cancer
Phase II Pre-operative Platform Trial in Surgically Resectable NSCLC
The Canadian Cancer Society (CCS) has renewed its support of the Canadian Cancer Trials Group (CCTG) with a five-year 30-million-dollar commitment to the national research network. The grant renewal represents a continuation of CCS’s largest research investment, which began in 1980 when they helped create the Canadian academic research group.
"CCS is proud to continue to provide core funding for CCTG, and we’re incredibly grateful to our donors who make this support possible," says Dr. Stuart Edmonds, Executive Vice President of Mission, Research & Advocacy at CCS. "With an international reputation for running Canada’s most impactful cancer clinical trials, CCTG’s work benefits not just people with cancer in Canada but around the world."
The grant renewal involves a rigorous review process that includes a comprehensive grant submission and site visit with external reviewers looking at all aspects of the Group’s work and impact on clinical trials research. The grant will support CCTG strategic objectives, and the development and conduct of trials.
Currently, the majority of ovarian cancers – upwards of 75 percent – are of the subtype “high grade serous carcinoma,” which is the type being treated in this phase 2 study.
CCTG is currently seeking volunteer Patient Representatives for the Brain Disease Site Committee (brain cancer) as well as for the Head and Neck Disease Site Committee (cancer inside the nose, throat or mouth). Patient Representatives participate in all aspects of disease site committee activities and are members of the CCTG Patient Representative Committee.
Annette Hay, Senior Investigator and Co-PI of ExCELLirate Canada, the CCTG-co-Led national platform for exploring the promising applications of cell therapy research across a wide variety of cancers and other illnesses was recently featured as a signature initiative at Queen’s University.
The CCTG BR34: A randomized phase II trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic non-small cell lung cancer study results were recently published in the Journal of Thoracic Oncology.
The CCTG CO29 trial, chaired in Canada by Dr. Jonathan Loree at BC Cancer, has been awarded $1,426,724 from the Canadian Institutes of Health Research (CIHR) Spring Project Competition.
Dr. Joseph Pater, is the recipient of the Canadian Cancer Society Lifetime Contribution Prize, a new honour from the Canadian Cancer Society (CCS).
Tailored Adjuvant Therapy in POLE-mutated and p53-wildtype/NSMP Early Stage Endometrial Cancer (TAPER)
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer (SELECT)
PembROlizumab with or without Microbial EcOsystem ThErapeutic 4 (MET4) in Advanced Head and Neck Squamous Cell Carcinoma (PROMOTE-HN)
Comparing Stereotactic Body Radiation Therapy (SBRT) to Standard Palliative Radiation Treatment (ON-TASC Study)
De-Escalation of ChemotheRapy in HER-2 positive, EStrogen reCEptor-negative, Node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and Dual HER-2 blOckade (DECRESCENDO)
Adjuvant Nivolumab with or without Cabozantinib in Patients with Resected Muscosal Melanoma
NET RETREAT: RCT of Lu-177 DOTATATE Retreatment vs. Everolimus in Metastatic/unresectable Small Bowel NET
Evaluating the Impact of SBRT with or without Nirapariib in Metastatic Hormone Sensitive Prostate Cancer Treated with ADT and Androgen Axis Directed Therapy
A Phase II Pre-operative Trial of JDQ433 in Surgically Resectable NSCLC
De-escalation of Breast Radiation for Conservative Treatment of Stage 1, HR+, HER2 -, RS =18 Breast Cancer (DEBRA)
Daratumumab/rHuPH20 + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs
Once the initial shock of a cancer diagnosis wears off, patients and families are left with questions. Lots and lots of questions. It might come as a relief to know that some of the most brilliant, accomplished scientists from around the world are listening.
“The biggest question we ask is the one that all cancer patients have,” says CCTG Scientific Director Dr. Janet Dancey. “What is the best treatment?”
Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.
Newly released clinical trial results show a substantial increase in survival rates for pancreatic cancer patients who received a four-drug chemotherapy combination known as mFOLFIRINOX after surgery.
Translational Lung Cancer Research 10: 826 - 838, 21 FFung AS;Karimi M;Michiels S;Seymour L;Brambilla E;Le-Chevalier T;Soria JC;Kratzke R;Graziano SL;Devarakonda S;Govindan R;Tsao MS;Shepherd FA;Collaborative Group obotL;
J Am Med Assoc 327: 1963 - 1973, 2022Goodwin PJ;Chen BE;Gelmon KA;Whelan TJ;Ennis M;Lemieux J;Ligibel JA;Hershman DL;Mayer IA;Hobday TJ;Bliss JM;Rastogi P;Rabaglio-Poretti M;Mukherjee SD;Mackey JR;Abramson VG;Oja C;Wesolowski R;Thompson AM;Rea DW;Stos PM;Shepherd LE;Stambolic V;Parulekar WR;
Eur J Can 170: 1 - 9, 2022Machingura A;Taye M;Musoro J;Ringash J;Pe M;Coens C;Martinelli F;Tu D;Basch E;Brandberg Y;Gr?nvold M;Eggermont A;Cardoso F;Van Meerbeeck J;van der Graaf WTA;Taphoorn M;Reijneveld JC;Soffietti R;Sloan J;Velikova G;Flechtner H;Bottomley A;
J Clin Oncol , 2022Liu JF;Brady MF;Matulonis UA;Miller A;Kohn EC;Swisher EM;Cella D;Tew WP;Cloven NG;Muller CY;Bender DP;Moore RG;Michelin DP;Waggoner SE;Geller MA;Fujiwara K;D'Andre SD;Carney M;varez Secord A;Moxley KM;Bookman MA;
Statist Med , 2022Wei K;Zhu H;Qin G;Zhu Z;Tu D;
Cancer Discovery : OF1 - OF10, 2022Grossmann KF;Othus M;Patel SP;Tarhini AA;Sondak VK;Knopp MV;Petrella TM;Truong TG;Khushalani NI;Cohen JV;Buchbinder EI;Kendra K;Funchain P;Lewis KD;Conry RM;Chmielowski B;Kudchadkar RR;Johnson DB;Li H;Moon J;Eroglu Z;Gastman B;Kovacsovics-Bankowski M;Gunturu KS;Ebbinghaus SW;Ahsan S;Ibrahim N;Sharon E;Korde LA;Kirkwood JM;Ribas A;
, 2022McBride SM;Niazi T;Williams S;Davis ID;Stockler M;Martin AJ;Bracken K;Roncolato FT;Horvath L;Sengupta S;Martin J;Lim T;Hughes S;McDermott RS;Catto JWF;Kelly PJ;Parulekar WR;Morgan SC;Rendon RA;Sweeney C;
J Immunother Cancer 10: e004310, 2022Tarhini AA;Lee SJ;Tan AC;El Naqa IM;Stephen Hodi F;Butterfield LH;LaFramboise WA;Storkus WJ;Karunamurthy AD;Conejo-Garcia JR;Hwu P;Streicher H;Sondak VK;Kirkwood JM;